Timothy Illidge Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 TIMOTHY ILLIDGE, Christie Hospital, Manchester Radioconjugated antibodies are showing grea
Timothy Illidge
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008TIMOTHY ILLIDGE, Christie Hospital, ManchesterRadioconjugated antibodies are showing great promise for treating follicular lymphoma which has failed chemotherapy combined with rituximab. That’s according toTim Illidgewho told the Paris conference that tositumomab and ibritumomab tiuxetan have already proved effective. He explained to Peter Goodwin why he thinks the latest data look promising.
Related Episodes
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy
Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers
“Adjuvant nivolumab added to chemoradiotherapy after surgery provided a statistically and clinically meaningful disease-free survival improvement in PD-L1 all-comers patients. This is the first time i
Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia
NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblast